Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
← catalyst calendarNCT02899052 · readout ≤ 315 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Genentech, Inc; Onyx Therapeutics, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
120estimated
Sites
32
Countries
Australia, Hungary, Puerto Rico +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-01-19 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2016-09-14 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Carfilzomib — also filed as Kyprolis
- Drug: Venetoclax — also filed as Venclexta, ABT-199
- Drug: Dexamethasone
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events
measured First dose of study drug through at least 30 days after end of treatment (approximately 2 years)
Very Good Partial Response (VGPR) or Better Response Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
measured First dose of study drug through at least 30 days after end of treatment (approximately 2 years)
Objective Response Rate (ORR) of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
measured First dose of study drug through at least 30 days after end of treatment (approximately 2 years)
Complete Response (CR) or Better Rate of VenKd in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) as well as Those with t(11;14)-positive RRMM
measured First dose of study drug through at least 30 days after end of treatment (approximately 2 years)
Publications
- PMID 39388024 — linked by the registry
- PMID 34470049 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed